GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Predictive Oncology Inc (NAS:POAI) » Definitions » Operating Margin %

Predictive Oncology (Predictive Oncology) Operating Margin % : -1,046.57% (As of Dec. 2023)


View and export this data going back to 2010. Start your Free Trial

What is Predictive Oncology Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Predictive Oncology's Operating Income for the three months ended in Dec. 2023 was $-3.51 Mil. Predictive Oncology's Revenue for the three months ended in Dec. 2023 was $0.34 Mil. Therefore, Predictive Oncology's Operating Margin % for the quarter that ended in Dec. 2023 was -1,046.57%.

Warning Sign:

Predictive Oncology Inc operating margin has been in a 5-year decline. The average rate of decline per year is -5.2%.

The historical rank and industry rank for Predictive Oncology's Operating Margin % or its related term are showing as below:

POAI' s Operating Margin % Range Over the Past 10 Years
Min: -1431.14   Med: -936.17   Max: -556.73
Current: -782.08


POAI's Operating Margin % is ranked worse than
91.89% of 814 companies
in the Medical Devices & Instruments industry
Industry Median: 1.275 vs POAI: -782.08

Predictive Oncology's 5-Year Average Operating Margin % Growth Rate was -5.20% per year.

Predictive Oncology's Operating Income for the three months ended in Dec. 2023 was $-3.51 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 was $-13.92 Mil.


Predictive Oncology Operating Margin % Historical Data

The historical data trend for Predictive Oncology's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Predictive Oncology Operating Margin % Chart

Predictive Oncology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -975.50 -997.12 -948.06 -1,014.49 -782.08

Predictive Oncology Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,220.11 -1,443.75 -774.69 -441.12 -1,046.57

Competitive Comparison of Predictive Oncology's Operating Margin %

For the Medical Instruments & Supplies subindustry, Predictive Oncology's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Predictive Oncology's Operating Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Predictive Oncology's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Predictive Oncology's Operating Margin % falls into.



Predictive Oncology Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Predictive Oncology's Operating Margin % for the fiscal year that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=-13.921 / 1.78
=-782.08 %

Predictive Oncology's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=-3.506 / 0.335
=-1,046.57 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Predictive Oncology  (NAS:POAI) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Predictive Oncology Operating Margin % Related Terms

Thank you for viewing the detailed overview of Predictive Oncology's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Predictive Oncology (Predictive Oncology) Business Description

Traded in Other Exchanges
N/A
Address
2915 Commers Drive, Suite 900, Eagan, MN, USA, 55121
Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Helomics, zPREDICTA, Soluble and Skyline. It derives prime revenue from the Skyline segment which consists of the STREAMWAY System product sales, and TumorGenesis subsidiary (Research and Development) is included within corporate. The STREAMWAY System virtually eliminates staff exposure to blood, irrigation fluid, and other potentially infectious fluids found in the healthcare environment. Its Helomics division is focused on improving the effectiveness of cancer therapy using proprietary, multi-omic tumor profiling platform, a one-of-a-kind database of historical tumor data, and the power of AI to build predictive models of tumor drug response.
Executives
Robert L Myers officer: CHIEF FINANCIAL OFFICER 4765 BEACON HILL ROAD, EAGAN MN 55122
Nuzum Charles Lee Sr director 633 1ST STREET WEST, SONOMA CA 95476
Veena Rao director 2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121
Matthew Hawryluk director C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608
St. Clair Gregory Sr director 1645 WHITLEY DRIVE, HARRISBURG PA 17111
Nancy Chung-welch director P O BOX 1572, PEPPERELL MA 01463
Pamela Bush officer: Chief Business Officer 2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121
Daniel E Handley director 1142 S. DIAMOND BAR BLVD. #464, DIAMOND BAR CA 91765
Raymond F Vennare director 2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121
David Stewart Smith director 151 WASHINGTON STREET, PITTSBURGH PA 15218
J Melville Engle director 1 REMINGTON COURT, NAPA CA 94558
Jenkins Christina Lee Md director 2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121
Carl I. Schwartz 10 percent owner 20155 N.E. 38TH COURT, UNIT 3104, AVENTURA FL 33180
Richard L Gabriel director 900 COCOANUT AVENUE, SARASOTA FL 34236
Pamela S Prior director 2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121

Predictive Oncology (Predictive Oncology) Headlines

From GuruFocus